ADRIACIN

Adriacin Adverse Events Reported to the FDA Over Time

How are Adriacin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Adriacin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Adriacin is flagged as the suspect drug causing the adverse event.

Most Common Adriacin Adverse Events Reported to the FDA

What are the most common Adriacin adverse events reported to the FDA?

Pneumonia	18 (3.25%)
Neoplasm Malignant	15 (2.71%)
Febrile Neutropenia	14 (2.53%)
Bone Marrow Failure	13 (2.35%)
Anaemia	9 (1.63%)
Herpes Zoster	9 (1.63%)
Interstitial Lung Disease	9 (1.63%)
Platelet Count Decreased	8 (1.45%)
White Blood Cell Count Decreased	8 (1.45%)
Cardiac Failure	7 (1.27%)
Death	7 (1.27%)
	Show More
Myelodysplastic Syndrome	7 (1.27%)
Pyrexia	7 (1.27%)
Vomiting	7 (1.27%)
Liver Disorder	6 (1.08%)
Metastases To Liver	6 (1.08%)
Respiratory Failure	6 (1.08%)
Tumour Lysis Syndrome	6 (1.08%)
Acute Myeloid Leukaemia	5 (.9%)
Anorexia	5 (.9%)
Cardiac Failure Acute	5 (.9%)
Cerebral Infarction	5 (.9%)
Constipation	5 (.9%)
Diarrhoea	5 (.9%)
Disseminated Intravascular Coagulat...	5 (.9%)
Liver Abscess	5 (.9%)
Loss Of Consciousness	5 (.9%)
Neutrophil Count Decreased	5 (.9%)
Sepsis	5 (.9%)
Thrombocytopenia	5 (.9%)
Allergic Cystitis	4 (.72%)
Atrial Fibrillation	4 (.72%)
Cardiomyopathy	4 (.72%)
Cystitis Haemorrhagic	4 (.72%)
Frontotemporal Dementia	4 (.72%)
Gamma-glutamyltransferase Increased	4 (.72%)
Malignant Neoplasm Progression	4 (.72%)
Pneumocystis Jiroveci Pneumonia	4 (.72%)
Pulmonary Oedema	4 (.72%)
Thrombosis	4 (.72%)
Tumour Embolism	4 (.72%)
Appendicitis	3 (.54%)
Cardiac Arrest	3 (.54%)
Convulsion	3 (.54%)
Dizziness	3 (.54%)
Melaena	3 (.54%)
Metabolic Acidosis	3 (.54%)
Monoplegia	3 (.54%)
Multi-organ Failure	3 (.54%)
Neutropenia	3 (.54%)
Olfactory Nerve Disorder	3 (.54%)
Pancytopenia	3 (.54%)
Septic Shock	3 (.54%)
Abasia	2 (.36%)
Abdominal Tenderness	2 (.36%)
Amyloidosis	2 (.36%)
Aortic Thrombosis	2 (.36%)
Asthenia	2 (.36%)
Blood Alkaline Phosphatase Increase...	2 (.36%)
Bone Sarcoma	2 (.36%)
Cardiac Failure Congestive	2 (.36%)
Cardiac Tamponade	2 (.36%)
Cerebrovascular Disorder	2 (.36%)
Clostridium Difficile Colitis	2 (.36%)
Colon Cancer	2 (.36%)
Cytomegalovirus Viraemia	2 (.36%)
Deep Vein Thrombosis	2 (.36%)
Depressed Level Of Consciousness	2 (.36%)
Disease Progression	2 (.36%)
Drug Ineffective	2 (.36%)
Empyema	2 (.36%)
Encephalopathy	2 (.36%)
Endotoxic Shock	2 (.36%)
Enterobacter Sepsis	2 (.36%)
Gastroenteritis Bacillus	2 (.36%)
Gastrointestinal Haemorrhage	2 (.36%)
Gastrointestinal Mucosal Disorder	2 (.36%)
Gingival Cancer	2 (.36%)
Grand Mal Convulsion	2 (.36%)
Hemiplegia	2 (.36%)
Hepatic Neoplasm Malignant Recurren...	2 (.36%)
Hepatitis	2 (.36%)
Hepatitis B	2 (.36%)
Hyperbilirubinaemia	2 (.36%)
Hypercholesterolaemia	2 (.36%)
Hyperphosphataemia	2 (.36%)
Hypertriglyceridaemia	2 (.36%)
Hypokalaemia	2 (.36%)
Hypoxia	2 (.36%)
Ileus Paralytic	2 (.36%)
Injection Site Pain	2 (.36%)
Intestinal Obstruction	2 (.36%)
Large Intestine Carcinoma	2 (.36%)
Lung Disorder	2 (.36%)
Metastases To Bone	2 (.36%)
Metastases To Lymph Nodes	2 (.36%)
Nasal Sinus Cancer	2 (.36%)
Oesophageal Carcinoma	2 (.36%)
Opportunistic Infection	2 (.36%)
Pancreatitis Acute	2 (.36%)
Pleural Effusion	2 (.36%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Adriacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Adriacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Adriacin

What are the most common Adriacin adverse events reported to the FDA?

Infections - Pathogen Unspecified	44 (7.96%)
Anemias Nonhemolytic And Marrow Dep...	25 (4.52%)
Hematology Investigations	24 (4.34%)
Miscellaneous And Site Unspecified ...	20 (3.62%)
White Blood Cell	19 (3.44%)
Viral Infectious	17 (3.07%)
Leukemias	16 (2.89%)
Lower Respiratory Tract Disorders	16 (2.89%)
Cardiac Arrhythmias	14 (2.53%)
Gastrointestinal Signs	14 (2.53%)
Heart Failures	14 (2.53%)
	Show More
Respiratory	14 (2.53%)
Hepatic And Hepatobiliary	13 (2.35%)
Gastrointestinal Motility And Defec...	12 (2.17%)
Metastases	12 (2.17%)
Electrolyte And Fluid Balance Condi...	11 (1.99%)
Neurological	11 (1.99%)
Embolism And Thrombosis	9 (1.63%)
Gastrointestinal Neoplasms Malignan...	9 (1.63%)
Movement Disorders	9 (1.63%)
Bacterial Infectious	8 (1.45%)
Bladder And Bladder Neck Disorders	8 (1.45%)
Central Nervous System Vascular	8 (1.45%)
Fatal Outcomes	8 (1.45%)
Body Temperature Conditions	7 (1.27%)
Gastrointestinal Hemorrhages	7 (1.27%)
Neoplasm Related Morbidities	7 (1.27%)
Appetite And General Nutritional	6 (1.08%)
Coagulopathies And Bleeding Diathes...	6 (1.08%)
Renal Disorders	6 (1.08%)
Fungal Infectious	5 (.9%)
Metabolic, Nutritional And Blood Ga...	5 (.9%)
Myocardial	5 (.9%)
Platelet	5 (.9%)
Seizures	5 (.9%)
Cranial Nerve Disorders	4 (.72%)
Decreased And Nonspecific Blood Pre...	4 (.72%)
Dental And Gingival Conditions	4 (.72%)
Gastrointestinal Ulceration And Per...	4 (.72%)
Hepatobiliary	4 (.72%)
Lipid Metabolism	4 (.72%)
Mental Impairment	4 (.72%)
Acid-base	3 (.54%)
Bone, Calcium, Magnesium And Phosph...	3 (.54%)
Enzyme	3 (.54%)
Exocrine Pancreas Conditions	3 (.54%)
Gastrointestinal Conditions	3 (.54%)
Gastrointestinal Stenosis And Obstr...	3 (.54%)
Hematological And Lymphoid Tissue T...	3 (.54%)
Hepatobiliary Neoplasms Malignant A...	3 (.54%)
Immune	3 (.54%)
Pericardial	3 (.54%)
Protein And Chemistry Analyses	3 (.54%)
Administration Site Reactions	2 (.36%)
Bone Disorders	2 (.36%)
Cardiac And Vascular Investigations	2 (.36%)
Encephalopathies	2 (.36%)
Gastrointestinal Tract Disorders Co...	2 (.36%)
Head And Neck Therapeutic Procedure...	2 (.36%)
Nephropathies	2 (.36%)
Pleural	2 (.36%)
Procedural And Device Related Injur...	2 (.36%)
Pulmonary Vascular	2 (.36%)
Renal And Urinary Tract Investigati...	2 (.36%)
Renal And Urinary Tract Neoplasms M...	2 (.36%)
Respiratory And Mediastinal Neoplas...	2 (.36%)
Skeletal Neoplasms Malignant And Un...	2 (.36%)
Therapeutic And Nontherapeutic Effe...	2 (.36%)
Vision	2 (.36%)
Water, Electrolyte And Mineral	2 (.36%)
Abdominal Hernias And Other Abdomin...	1 (.18%)
Allergic Conditions	1 (.18%)
Bile Duct	1 (.18%)
Breast Neoplasms Malignant And Unsp...	1 (.18%)
Cardiac Disorder Signs	1 (.18%)
Central Nervous System Infections A...	1 (.18%)
Deliria	1 (.18%)
Endocardial	1 (.18%)
Gastrointestinal Vascular Condition...	1 (.18%)
Headaches	1 (.18%)
Hematopoietic Neoplasms	1 (.18%)
Immunodeficiency Syndromes	1 (.18%)
Increased Intracranial Pressure And...	1 (.18%)
Inner Ear And Viiith Cranial Nerve	1 (.18%)
Medication Errors	1 (.18%)
Musculoskeletal And Connective Tiss...	1 (.18%)
Nervous System Neoplasms Malignant ...	1 (.18%)
Oral Soft Tissue Conditions	1 (.18%)
Peritoneal And Retroperitoneal Cond...	1 (.18%)
Physical Examination Topics	1 (.18%)
Plasma Cell Neoplasms	1 (.18%)
Skin Appendage Conditions	1 (.18%)
Upper Respiratory Tract Disorders	1 (.18%)
Urinary Tract Signs	1 (.18%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Adriacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Adriacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.